Novo Nordisk (NVO) Seeks FDA Approval for Oral Wegovy

 

• Novo Nordisk (NVO, Financial) is seeking FDA approval for an oral version of its GLP-1 weight-loss drug, Wegovy.
• Analysts offer a positive outlook with an average price target significantly above the current market price.
• GuruFocus estimates indicate a potential substantial upside based on GF Value analysis.

Novo Nordisk (NVO) has made a strategic move by filing for U.S. FDA approval of an oral formulation of its highly-regarded GLP-1 weight-loss treatment, Wegovy. This filing follows impressive phase 3 clinical trial results announced in May that demonstrated notable weight reduction benefits. Novo Nordisk's application comes amid rising competition, particularly from Eli Lilly, which has also reported successful phase 3 results for its GLP-1 treatment.

https://www.gurufocus.com/news/2791663/novo-nordisk-nvo-seeks-fda-approval-for-oral-wegovy